Transaction details
Altimmune, Inc. (NASDAQ: ALT) director John Gill reported the acquisition of 9,200 shares of the company's common stock on April 6, 2026. The shares were acquired at prices ranging from $3.4050 to $3.4080, bringing the aggregate cost of the purchase to $31,349. After the transaction, Gill's direct ownership in Altimmune stands at 21,700 shares.
Market context and valuation note
The purchase comes against a backdrop in which Altimmune's stock has rallied more than 15% over the previous week. At the same time, InvestingPro analysis flagged that the shares may be overvalued at current levels.
Balance-sheet snapshot
InvestingPro data also indicates that Altimmune holds more cash than debt on its balance sheet - a detail listed as one of 12 key ProTips available to subscribers analyzing this $433 million biotech firm.
Recent financial results
Altimmune reported fourth-quarter 2025 earnings that fell short of expectations. The company recorded earnings per share (EPS) of -$0.27, missing the forecasted -$0.25 and producing an EPS surprise of -8%. Revenue for the quarter was reported at $26 million versus an anticipated $625 million, representing a significant shortfall versus consensus estimates.
Analyst perspectives
Several firms have weighed in on Altimmune's outlook following the results and development updates. Jefferies reiterated a Buy rating with a $28 price target, noting the company's progression toward a Phase 3-ready position and reduced financing concerns. Truist Securities initiated coverage with a Buy rating and a $12 target, citing the potential of Altimmune's lead asset, pemvidutide, in treating liver-related diseases. H.C. Wainwright raised its price target to $25 from $12 while maintaining a Buy rating and highlighted the company's focus on a planned MASH pivotal program. William Blair reiterated a Market Perform rating after trial results for pemvidutide, noting the competitive landscape in the MASH market.
What this means going forward
The insider purchase increases a director's direct holdings and coincides with both a recent share-price rally and a set of mixed signals from quarterly financials and external analysis. The company faces near-term scrutiny on revenue performance and market expectations as it advances clinical programs.
Key points
- Director John Gill bought 9,200 Altimmune shares on April 6, 2026, paying $3.4050 to $3.4080 per share for a total of $31,349.
- Altimmune reported Q4 2025 EPS of -$0.27 (miss) and revenue of $26 million versus $625 million expected; several analysts provided Buy or Market Perform ratings with varied price targets.
- Sectors impacted include biotechnology and broader healthcare equities, with market valuation and capital-markets sentiment likely influenced by the results and analyst commentary.
Risks and uncertainties
- Near-term financial risk from missed EPS and dramatic revenue shortfall could pressure investor sentiment in biotech and healthcare sectors.
- Valuation concerns noted by InvestingPro - the shares may be overvalued at current levels, introducing market-risk for equity holders.
- Competitive dynamics in the MASH (metabolic dysfunction-associated steatohepatitis) market and trial outcomes create clinical and commercial uncertainty affecting the company's outlook.